After finishing at $36.52 in the prior trading day, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $36.28, down -0.66%. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 902611 shares were traded. ARWR stock price reached its highest trading level at $38.55 during the session, while it also had its lowest trading level at $36.27.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ratios:
Our goal is to gain a better understanding of ARWR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.60 and its Current Ratio is at 6.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 05 when GIVEN DOUGLAS B sold 6,500 shares for $40.90 per share. The transaction valued at 265,850 led to the insider holds 117,635 shares of the business.
Anzalone Christopher Richard sold 50,000 shares of ARWR for $1,975,792 on May 04. The Chief Executive Officer now owns 3,761,338 shares after completing the transaction at $39.52 per share. On May 03, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 54,928 shares for $39.14 each. As a result, the insider received 2,149,882 and left with 3,761,338 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 3.83B and an Enterprise Value of 3.42B. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.22 while its Price-to-Book (P/B) ratio in mrq is 8.68. Its current Enterprise Value per Revenue stands at 12.54 whereas that against EBITDA is -25.22.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $48.48, while it has fallen to a 52-week low of $23.09. The 50-Day Moving Average of the stock is 31.29, while the 200-Day Moving Average is calculated to be 33.91.
Shares Statistics:
The stock has traded on average 1.16M shares per day over the past 3-months and 834.09k shares per day over the last 10 days, according to various share statistics. A total of 106.76M shares are outstanding, with a floating share count of 103.30M. Insiders hold about 3.40% of the company’s shares, while institutions hold 68.10% stake in the company. Shares short for ARWR as of Apr 27, 2023 were 4.84M with a Short Ratio of 4.84M, compared to 4.96M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.53% and a Short% of Float of 5.40%.
Earnings Estimates
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$0.7 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$1.27, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.12 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$0.09 and -$2.49 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$2.86, with 11 analysts recommending between $0.19 and -$4.33.
Revenue Estimates
10 analysts predict $48.48M in revenue for the current quarter. It ranges from a high estimate of $109.8M to a low estimate of $7.75M. As of the current estimate, Arrowhead Pharmaceuticals Inc.’s year-ago sales were $32.41M, an estimated increase of 49.60% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $43.42M, an increase of 37.50% less than the figure of $49.60% in the same quarter last year. There is a high estimate of $109.8M for the next quarter, whereas the lowest estimate is $3.7M.
A total of 12 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $428.5M, while the lowest revenue estimate was $208M, resulting in an average revenue estimate of $283.35M. In the same quarter a year ago, actual revenue was $243.23M, up 16.50% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $180.19M in the next fiscal year. The high estimate is $440.1M and the low estimate is $45.5M. The average revenue growth estimate for next year is down -36.40% from the average revenue estimate for this year.
